Cerebras Systems designs and manufactures AI accelerator chips, and its first earnings report as a public company is driving sharp scrutiny this week. Despite beating revenue estimates and narrowing its net loss in the first quarter of 2026, shares of Cerebras Systems Inc. (NASDAQ:CBRS) dropped hard on the results, as a deteriorating gross margin outlook overshadowed the headline beat.
At a Glance
- CBRS closed at $188.56, off 16.8% on the session, touching its lowest level since its recent IPO
- 52-week range: $185.22 to $386.34, with the stock now sitting just above its range floor
- Market cap: $49.79 billion
- Q1 2026 revenue of $193.4 million beat the Visible Alpha consensus by roughly $10 million
- Adjusted gross margin guidance for Q2: 36% to 38%, down from 47% in Q1
| Price | 188.56 USD |
|---|---|
| Day change | -38.08 (-16.8%) |
| 52-week range | 185.22 – 386.34 |
| Market cap | $49.79B |
| RSI (14) | 34.13 |
| Volume | 14,583,022 |
A Beat That the Market Is Punishing
Cerebras reported Q1 revenue of $193.4 million, approximately $10 million above the analyst consensus compiled by Visible Alpha. The adjusted net loss came in at $2.48 million, narrower than Wall Street had expected. On the surface, those are clean numbers for a company's debut quarterly report.
The problem is what comes next. Management guided Q2 adjusted gross margins in the 36% to 38% range, a meaningful step down from the 47% margins the company achieved in Q1. For a chipmaker still establishing its cost structure as a public company, a roughly 10 percentage point margin compression in a single quarter raises questions about scalability and pricing power. That guidance appears to be what moved investors, not the backward-looking beat.
The selloff extends a rough stretch for CBRS since its IPO. Wednesday's move leaves the stock down nearly 40% from its first-day closing price and just about 4% above its IPO price of $185. At $188.56, the shares are hovering near existential support: the 52-week low sits at $185.22, only $3.34 below Friday's close.
What the Numbers Say
Valuation. At a market cap of $49.79 billion against trailing quarterly revenue of $193.4 million, Cerebras carries a price-to-sales multiple that reflects aggressive growth expectations. No P/E ratio applies here given the company is still operating at a loss, making forward revenue growth and the path to profitability the central valuation variables. Any compression in gross margin makes that path longer.
Momentum. The RSI reading of 34.13 places CBRS just above the conventional oversold threshold of 30. That level can attract technically oriented buyers looking for a mean reversion, but it can also reflect genuine deterioration in sentiment rather than a temporary dip. Given the proximity to the 52-week low, the RSI is more a caution flag than a contrarian signal in isolation.
Yield. Cerebras pays no dividend, consistent with a growth-stage company that is still burning cash. Investors in CBRS are buying a capital appreciation thesis, not an income stream, which means the margin outlook and revenue trajectory carry the full weight of the valuation.
Morgan Stanley Stays Bullish, Raises Target
Not everyone read the print negatively. Morgan Stanley analysts told clients Wednesday they remain constructive on the stock and lifted their price target to $273 from $250, citing strong demand for Cerebras chips. Their note argued that nothing in the numbers was actually disappointing and suggested the company may be issuing conservative guidance as it finds its footing through its first few public quarters. A $273 target against the current price of $188.56 implies roughly 45% upside from here, which is a meaningful call given the volatility the stock has already seen.
Bull Case vs. Bear Case Risks
The bull case rests on chip demand. If Cerebras can demonstrate that the Q2 margin compression is transitional rather than structural, and if the revenue trajectory holds, the current price near the IPO floor could look like a compressed entry point relative to where the stock traded earlier in its brief public life. Morgan Stanley's demand commentary supports that reading.
The bear case is simpler. A company that guided gross margins down by roughly 10 percentage points one quarter into public life has introduced real uncertainty about its cost structure. With no earnings, no dividend, and a stock already trading 40% below its first-day close, the downside scenario involves a prolonged search for a floor at or below the IPO price. The 52-week low of $185.22 is now the obvious line in the sand.
Frequently Asked Questions
Why did Cerebras stock drop after beating earnings?
Investors reacted to forward guidance rather than the Q1 beat. Management projected Q2 adjusted gross margins of 36% to 38%, down from 47% in Q1, raising concerns about cost pressures and near-term profitability.
How does CBRS compare to its IPO price?
At $188.56, CBRS is trading roughly 4% above its IPO price of $185 and about 40% below its first-day closing price, reflecting significant volatility since the company began trading last month.
What is Morgan Stanley's price target for Cerebras?
Morgan Stanley raised its price target to $273 from $250 on Wednesday, citing strong chip demand and suggesting the company's guidance may be conservatively set.
Is Cerebras profitable?
Not yet. The company reported an adjusted net loss of $2.48 million in Q1 2026. It carries no P/E ratio and pays no dividend, so the investment case is entirely forward-looking.
Where CBRS Goes From Here
With the stock pressing against the bottom of its 52-week range and gross margin guidance moving in the wrong direction, the next few quarters will be decisive for how the market prices Cerebras' long-term potential. The Q1 revenue beat and Morgan Stanley's conviction provide a counterweight, but the margin trajectory is now the number that investors will track most closely.
